» Articles » PMID: 18803350

"Rescue" Regimens After Helicobacter Pylori Treatment Failure

Overview
Specialty Gastroenterology
Date 2008 Sep 23
PMID 18803350
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Helicobacter pylori (H pylori) infection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After more than 20 years of experience in H pylori treatment, in my opinion, the ideal regimen to treat this infection is still to be found. Currently, apart from having to know first-line eradication regimens well, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a "rescue" treatment depends on which treatment is used initially. If a clarithromycin-based regimen was used initially, a subsequent metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin-based combination would be a third "rescue" option. Alternatively, it has recently been suggested that levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, a quadruple regimen may be reserved as a third-line rescue option. Finally, rifabutin-based rescue therapy constitutes an encouraging empirical fourth-line strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H pylori eradication can finally be achieved in almost all patients if several rescue therapies are consecutively given. Therefore, the attitude in H pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.

Citing Articles

Vonoprazan-amoxicillin dual regimen with as a rescue therapy for : Current perspectives and implications.

Dirjayanto V, Audrey J, Simadibrata D World J Gastroenterol. 2024; 30(10):1280-1286.

PMID: 38596495 PMC: 11000074. DOI: 10.3748/wjg.v30.i10.1280.


Research on antibiotic resistance in : a bibliometric analysis of the past decade.

Yuan C, Yu C, Sun Q, Xiong M, Zhou S, Zeng M Front Microbiol. 2023; 14:1208157.

PMID: 37389333 PMC: 10301835. DOI: 10.3389/fmicb.2023.1208157.


Recombinant Vaccine Delivery Vehicle: A Promising Tool to Treat Infections and Combat Antimicrobial Resistance.

Dieye Y, Nguer C, Thiam F, Diouara A, Fall C Antibiotics (Basel). 2022; 11(12).

PMID: 36551358 PMC: 9774608. DOI: 10.3390/antibiotics11121701.


rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy.

Sue S, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S JGH Open. 2021; 5(2):307-311.

PMID: 33553672 PMC: 7857288. DOI: 10.1002/jgh3.12492.


Rifabutin for the Treatment of Infection: A Review.

Gisbert J Pathogens. 2020; 10(1).

PMID: 33379336 PMC: 7823349. DOI: 10.3390/pathogens10010015.


References
1.
Vakil N, Hahn B, McSorley D . Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998; 93(9):1432-5. DOI: 10.1111/j.1572-0241.1998.455_t.x. View

2.
Lam S, Talley N . Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998; 13(1):1-12. DOI: 10.1111/j.1440-1746.1998.tb00537.x. View

3.
Battaglia G, Di Mario F, Vigneri S, Vianello F, Benvenuti M, Donisi P . Strategy for the retreatment of failed Helicobacter pylori eradication therapy: a case series. Ital J Gastroenterol Hepatol. 1998; 30(4):370-4. View

4.
Laine L, Suchower L, Frantz J, Connors A, Neil G . Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. Am J Gastroenterol. 1998; 93(11):2106-12. DOI: 10.1111/j.1572-0241.1998.00602.x. View

5.
Howden C, Hunt R . Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998; 93(12):2330-8. DOI: 10.1111/j.1572-0241.1998.00684.x. View